KR20190020631A - Composition containing phlorotannin for health of female reproductive organs and product thereof - Google Patents

Abstract

The present invention relates to: a composition for maintaining and improving female genital health, which is capable of preventing and alleviating various symptoms of female vaginitis and reducing menstrual pain, menstrual irregularities, and percutaneous toxicity caused by use of sanitary pads; and a product comprising the composition. More specifically, the present invention relates to the composition and a related product for preventing and alleviating vaginitis and alleviating symptoms related to menstruation, wherein the composition containing phlorotannin as an active component is applied to female genitals in a form of a liquid agent which can be applied by a method such as spraying, dispersing on a surface of a sanitary pad, injection or the like.

Description

[0001] The present invention relates to compositions and products for maintaining or improving female reproductive health, comprising phlorotannin as an active ingredient,

The present invention relates to a composition for maintaining and improving female reproductive health, which can prevent and improve various symptoms of vaginitis and menstrual period which are typical factors threatening female reproductive health, and a product containing the composition. The present invention relates to a composition and a product which are safe and have excellent antimicrobial action without the problem of side effects of existing products including chemicals such as preservatives, antibiotics, cleaning agents and VOCs.

Female genitalia The most common cause of harm to health is vaginitis. Bacterial vaginitis is one of the most common female vaginas. Lactobacillus that controls pH in vagina disappears and the number of anaerobic bacteria increases exponentially. Bacterial vaginosis causes symptoms such as burning sensation, pain, edema, odor, abnormal vaginal discharge, and the like. Seventy percent of women around the world have been reported to have bacterial pneumonia. In addition, vaginitis causes various complications. Specifically, when the vaginitis becomes worse, the risk of pelvic inflammation increases and the infection increases after the operation related to the uterus. In pregnant women, premature rupture of membranes, premature labor, and endometritis after cesarean section It is accompanied by many complications.

To improve symptoms of vaginitis, 43.9% of all ages are known to use vaginal detergents. Metronidazole antibiotics are usually used to treat vaginitis. The use of these antibiotics causes side effects such as nausea, vomiting, diarrhea, gastrointestinal disturbances, hand tremors, and numbness. Above all, women's cleaners and antibiotics also kill lactic acid bacteria (Lactobacillus bacteria), which maintain a normal environment in the vagina due to their powerful sterilizing action. Lactobacillus, a lactic acid bacterium, is rarely regenerated once it dies and it causes obstacles to restoration of vaginal health. In addition, chemical agents such as fatty acids, lauryl alcohol, and organic disinfectants contained in cleansers and local cleansers used for improving the quality of the vagina can act on the skin to detach keratin and dissolve the fat, causing dryness and itching of the skin . Due to these side effects, many products using natural extract have recently been developed, but they are disadvantageous in that the effect is insignificant, the application method is inconvenient or complicated and the convenience of the user is poor.

Female genitalia Another important factor that harms the health is excessive menstrual cramps, psychological instability, menstrual irregularities during the menstruation period, and percutaneous toxicity by wearing sanitary napkins. These physiological symptoms and bacterial vaginitis can be combined factors that harm the health of female genitalia by forming causal feedback with each other. Especially, it is known that harmful substances such as VOC, which are generated in a mass-produced sanitary napkin in recent years, cause percutaneous toxicity around female reproductive organs, making it more difficult to maintain female reproductive health.

In order to solve the problems of toxic chemicals used in various products used for the treatment of female genital diseases and health maintenance, it is not toxic, and has excellent therapeutic effect of yeast infection. It is urgent to develop new materials and related products that can prevent female genital diseases and improve health.

Korean Patent Publication No. 2009-0125865

The present invention relates to a method for preventing and improving symptoms of vaginitis and menstruation which are factors threatening the health of female reproductive organs without causing the side effects of existing products including preservatives, antibiotics, bactericides, organic solvents and surfactants, And to provide a composition capable of maintaining and improving reproductive health. In addition, it improves the disadvantages of existing inconvenient products and easily contributes to maintenance and improvement of female reproductive health by preventing vaginitis and alleviating symptoms of menstruation.

To achieve the above object, the present invention provides a composition for maintaining or improving female reproductive health comprising a phlorotannin compound as an active ingredient

The present invention also provides a product for maintaining or improving female reproductive health comprising said composition.

The composition and the product containing the phlorotannin of the present invention as an active ingredient are free from any adverse effects due to no preservatives, antibiotics or chemical cleansing agents, and can be applied to the vulva or directly injected into the vagina, And provides an improvement effect. In addition, it has an effect of contributing to the genital health of a woman by providing an effect of mitigating menstrual symptoms by applying to a sanitary napkin.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is an example of the spray-type female cleanser of the present invention.
Fig. 2 is an example of the disposable injection-container type female cleaner of the present invention.
3 is an example of a sanitary napkin product of the present invention.

Hereinafter, the present invention will be described in detail.

The major causes and symptoms of harming female reproductive organs and the problems of the prior art are analyzed as follows.

1. Due to the use of antibiotics, Lactobacillus, which is a beneficial bacteria in vagina, also disappeared, resulting in a natural restoration of vaginal health.

2. Women's cleaners, chemical preservatives such as preservatives in vaginal cleansers, and VOCs from sanitary nets inhibit sensitive skin around female genitalia.

3. Excessive menstrual pain during the menstruation period, psychological instability, impaired reproductive health due to physiological impoverishment.

The three problems mentioned above are universal exposure of modern women. The above three problems can be regarded as independent problems on the surface, but since the skin around the female genitalia has a significantly higher permeability and sensitivity than the normal skin, the above problems constitute a repetitive feedback structure between the female genitalia It can form a vicious circle of health deterioration.

Therefore, the inventors of the present invention have found that not only the safety is ensured but also the fact that the phlorotannin component extracted from brown algae exerts an excellent effect after studying natural ingredients capable of simultaneously eliminating or alleviating the above three problems, Thereby completing the present invention.

The composition comprising the fluorotannine of the present invention as an active ingredient helps maintain the reproductive health of the female and improves reproductive health.

The composition for improving and maintaining female reproductive health may contain 20-100 wt% of a fluorotannine compound.

The above-mentioned phlorotannin can be obtained by any conventional method as a naturally occurring component. That is, it may be synthesized using a commercially available reagent, or may be obtained by extraction and separation from natural products, particularly seaweeds.

The phlorotannin can be extracted from seaweeds, especially brown algae. Specifically, the phlorotannine can be extracted from seaweeds, especially brown algae, and specifically includes Eisenia bicyclis , Eisenia arborea , Eisenia desmarestioides , Eisenia galapagensis , Eisenia masonii , Ecklonia kurome , Ecklonia cava , Ecklonia stolonifera , Ecklonia maxima , Ecklonia radiata , For example, Ecklonia bicyclis , Ecklonia biruncinate , Ecklonia buccinalis , Ecklonia caepaestipes , Ecklonia exasperta , , Eccles Catalonia parse tee starvation other (Ecklonia fastigiata), Eccles Catalonia breather bipseu (Ecklonia brevipes), Eccles Catalonia Ara beam LEA (Ecklonia arborea), Eccles One member selected from the group consisting of California Lahti polyamic (Ecklonia latifolia), Eccles Catalonia Mura tea (Ecklonia muratii), Eccles Catalonia radio Kosa (Ecklonia radicosa), Eccles Catalonia retarder Diana (Ecklonia richardiana) and Eccles Catalonia La ET (Ecklonia wrightii) .

In addition to phlorotannin, the composition of the present invention may further contain 0 to 80% by weight of a component composed of mannitol, alginic acid, fucoidan, laminaran, and fucosterol, fucosanthin and the like as lipid components.

The composition of the present invention may contain at least one phlorotannin selected from compounds represented by the following general formulas (1) to (12) as an active ingredient.

[Chemical Formula 1]

(2)

(3)

[Chemical Formula 4]

[Chemical Formula 5]

[Chemical Formula 6]

(7)

[Chemical Formula 8]

[Chemical Formula 9]

[Chemical formula 10]

(11)

[Chemical Formula 12]

The composition of the present invention may contain at least one kind of phlorotannin selected from the above-mentioned formulas (2), (4), (5) and (8) as an effective ingredient.

The composition of the present invention may contain two or more kinds of phlorotannines selected from the above-mentioned formulas (2), (4), (5) and (8) as effective ingredients.

The composition of the present invention comprises 1-60% by weight of a fluorotannin of the formula (2), 0.3-20% by weight of a fluorotannin of the formula (4), 0.1-10% by weight of a fluorotannin of the formula (5) 0.1 to 5% by weight of tannin.

The composition of the present invention may contain 1-65 wt% of fluorotannine of Formula 2 and 0.3-45 wt% of fluorotannin of Formula 4, based on the total weight.

The composition of the present invention may contain 1-45 wt% of fluorotannine of Formula 5 and 0.3-45 wt% of fluorotannine of Formula 8, based on the total weight.

The composition of the present invention comprises 0.1 to 3% by weight of a fluorotannine of the formula (1), 5 to 63% by weight of a fluorotannin of the formula (2), 1 to 3% by weight of a fluorotannin of the formula (3) , Tannin 0.5 to 34 wt.%, Fluorotannine 0.1 to 50 wt.% Of formula 5, fluorotannine 0.5 to 8 wt.% Of formula 6, fluorotannine 0.1 to 1 wt.% Of formula 7, 0.1 to 3% by weight of a fluorotannine of formula (11), 0.1 to 4% by weight of a fluorotannin of formula (12), 0.1 to 2% % ≪ / RTI > by weight.

The composition of the present invention comprises 20 to 100% by weight of phlorotannin, 0 to 30% by weight of mannitol, 0 to 25% by weight of alginic acid, 0 to 25% by weight of fucoidan, 0 to 10% by weight of fucosterol, 0 to 10% , And 0 to 10% by weight of laminaran.

The composition of the present invention comprises 20 to 97% by weight of phlorotannin, 1 to 30% by weight of mannitol, 1 to 25% by weight of alginic acid, 0.5 to 25% by weight of fucoidan, 0.1 to 10% by weight of fucosterol, 0.1 to 10% And 0.1 to 10% by weight of the laminate.

The present invention provides a product for maintaining and improving female reproductive health comprising the above-mentioned flurotanin composition.

The product may be in the form of a spray liquid product, an injection liquid product, a sanitary napkin, or the like.

When the product is a liquid body, the content of the float tannin may be 0.01 to 5% by weight, preferably 0.02 to 4% by weight, more preferably 0.03 to 3% by weight based on the total weight of the product. When the content of phlorotannin is included in the above amount, the effect of maintaining and improving female reproductive health is excellent.

When the product is applied to the sanitary napkin, when the fluorotannine is applied to the sanitary napkin at a concentration of 0.001 to 1 mg / cm ² , the female genital health is improved and the effect is improved.

The product of the present invention may further contain 0.001 to 0.5% by weight of ascorbic acid.

The fluorotannine composition may be commercialized in the form of a liquid cleanser. That is, the flurothanine composition of the present invention can be commercialized as a liquid cleansing agent containing citrus peel oil, ethanol, mandarin orange extract, ascorbic acid, and can be applied as a spray or disposable injection bar. It can also be applied as a product applied to a sanitary napkin for women.

The daily use amount of the phlorotannin contained in the product for maintaining and improving the female reproductive health of the present invention is preferably about 0.1 to 50 mg, but the dosage is not limited to the above range. When the daily dose is within the above range, the female genital health is excellent in maintaining and improving the health.

Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are intended to further illustrate the present invention, and the scope of the present invention is not limited by the following examples. The following examples can be appropriately modified and changed by those skilled in the art within the scope of the present invention.

Example 1. Preparation of a composition containing fluorotannine

In order to prepare a composition containing the phlorotannin of the present invention as an active ingredient, the brown algae of the present invention were extracted by the following method.

Ecklonia cava was washed with distilled water to remove foreign matter, dried in shade, and then shattered. 500 g of the above menthol was added to the extraction container, 20 times of 30 wt% aqueous solution of menthol was added thereto, and the mixture was refluxed at 75 to 80 ° C for 4 hours to obtain an extract. The extract was filtered through a filter net of 10 mu m, and the filtered extract was concentrated under reduced pressure to obtain a primary extract concentrate. The primary extract concentrate was dried with a vacuum drier and pulverized to obtain 170 g of Composition 1.

The composition 1 was dissolved in hot water at 50 캜, adsorbed on an adsorption resin, washed with water, and eluted with a solvent to obtain a fluorotannine eluant. The eluate was filtered through a 1 탆 filter net, and the filtered extract was concentrated under reduced pressure to obtain a second extract concentrate. The second extraction concentrate was dried with a vacuum drier and pulverized to obtain 30 g of Composition 2.

Then, the composition 2 was suspended in 20 times as much distilled water and extracted three times with the same amount of ethyl acetate solvent to obtain an ethyl acetate fraction. The ethyl acetate fraction was concentrated under reduced pressure, and the concentrate was dried with a vacuum drier and pulverized to obtain 10 g of Composition 3.

Composition 3 was dissolved in 30 vol% methanol and the compositions 4 and 5 were separated using reverse phase chromatography. Separation was carried out by using a 15 to 80% by volume methanol aqueous solution and 2 g of Composition 4 was obtained by concentrating the solution separated by the methanol aqueous solution of 15 to 30% by volume concentration. The solution separated from the methanol aqueous solution of 30 to 80% To obtain 7 g of Composition 5.

Each of the compositions 1 to 5 prepared above was loaded on liquid chromatography to proceed with compound separation. The compounds thus obtained were identified as the compounds of the formulas (1) to (12) using the NMR spectroscopic analysis apparatus. Each of the above compositions 1 to 5 was dissolved in 60% by volume methanol, filtered through a 0.2 μm membrane filter, and loaded onto high performance liquid chromatography. In high performance liquid chromatography, HP ODS Hypersil was used as the column, distilled water and methanol were used as the solvent, and the solvent was fed from a linear gradient of from 15 vol% to 70 vol% of methanol for 30 minutes at a flow rate of 1.0 ml / ). As a result, the presence of the compounds of Formulas 1 to 12 was confirmed. The chemical compositions of the above-mentioned compositions 1 to 5 are shown in Table 1 below.

sample Composition of sample Composition 1 20% by weight of total fluorotannine containing 2% by weight of the formula 2, 1% by weight of the formula 4, 0.5% by weight of the formula 5, 0.3% by weight of the formula 8 and 16.2% by weight of the single compound of the formula 1-12, , 20% by weight of alginic acid, 20% by weight of fucoidan, 5% by weight of fucosterol, 5% by weight of fucoxanthin, 5% Composition 2 70% by weight of total fluorotannine, 10% by weight of mannitol, 3% by weight of the compound of formula (2), 3% by weight of the compound of formula (4) , 6% by weight of alginic acid, 6% by weight of fucoidan, 3% by weight of fucosterol, 3% by weight of fucozanthin, 2% Composition 3 100% by weight of total fluorotannin including 17% by weight of Formula 2, 5% by weight of Formula 4, 5% by weight of Formula 5, 3% by weight of Formula 8, and 70% Composition 4 100% by weight of total fluorotannin including 50% by weight of the formula (5), 46% by weight of the formula (8) and 4% by weight of the single compound of the formula (1-12) Composition 5 100% by weight of total fluorotannin containing 63% by weight of the formula (2), 34% by weight of the formula (4) and 3% by weight of the single compound of the formula (1-12)

Example 2. Evaluation of antimicrobial activity of the composition

The antimicrobial effect of the composition of Example 1 on the causative agent of vaginitis was evaluated as follows.

The antimicrobial effect of the composition of Example 1 against three major strains of Candida albicans (ATCC 10231), Candida glabrata (ATCC 2001) and Candida tropicalis (ATCC 42678) was evaluated. The Candida bacteria used in the experiment were purchased from the Korean Microorganism Conservation Center and cultured for 3 or more times. When normal culture of the strain was confirmed, the culture broth was cultured in a medium containing 0.5% by weight of the composition 1 to 5 (YM broth, YM agar) and a composition-free medium (control), and cultured with shaking at 25 ° C for 24 hours. After cultivation was completed, the cells were plated on agar medium and cultured at 25 ° C. for 48 hours or more. The antimicrobial effect of the composition of Example 1 is shown in Table 2.

Strain Control Composition 1 Composition 2 Composition 3 Composition 4 Composition 5 Candida albicans 1.6 x 10 ⁶ 45% reduction 68% reduction 89% reduction 91% reduction 90% reduction Candida glabrata 3.7 x 10 ⁶ 40% reduction 72% reduction 96% reduction 94% reduction 97% reduction Candida tropicalis 6.6 x 10 ⁶ 37% reduction 64% reduction 97% reduction 98% reduction 95% reduction

* Unit: CFU / mL

Example 3 Evaluation of improving effect of the composition on the survival rate of Lactobacillus bacteria

The effect of improving the survival rate of the lactobacillus bacteria against the composition of Example 1 was evaluated as follows.

The survival rates of three different species of Lactobacillus brevis (ATCC 8287), Lactobacillus pentosus (ATCC 8041) and Lactobacillus plantarum (ATCC 8014) were evaluated. The Lactobacillus spp. Used in the experiment was subcultured more than 3 times after the purchase at the Korean Microorganism Conservation Center. When normal culture of the strain was confirmed, the culture broth was cultured in a medium containing 1 wt% of the composition 1 to 5 (MRS broth, MRS agar) and a composition-free medium (control) and cultured at 30 ° C for 24 hours with shaking. After cultivation was completed, the cells were plated on agar medium and cultured at 30 ° C. for 24 hours or more. Table 3 shows the effect of improving the survival rate of Lactobacillus bacteria against the composition of Example 1. The survival rate of Lactobacillus was expressed as a ratio to the number of colonies in the control.

As shown in the results of Examples 2 and 3, it can be seen that the composition of the present invention maintains or increases the lactobacillus, which is a beneficial bacteria, but exhibits an excellent antimicrobial effect against vaginitis-causing bacteria, and thus can be effectively used for treating vaginitis without side effects.

Strain Survival rate of Lactobacillus (%) Control Composition 1 Composition 2 Composition 3 Composition 4 Composition 5 Lactobacillus brevis 100 295 178 118 114 120 Lactobacillus pentosus 100 240 149 110 107 106 Lactobacillus plantarum 100 281 163 104 116 110

* Unit: CFU / mL

Example 4. Preparation of female genital health improving agent using composition

A composition containing the floatotinin of Example 1 and ascorbic acid were added to about 99 g of water and mixed until completely dissolved. When fully mixed, citrus peel oil and mandarin orange extract were added to a trace amount of ethanol, and then stirred until thoroughly mixed. When the ethanol, the citrus peel oil, and the orange extract were completely mixed, the composition containing the phlorotannin was added to the dissolved solution and stirred until it was completely mixed. The completed solution was used in the form of a spray bottle and a disposable injection container. The composition of the female genital health improver using the composition is shown in Table 4 below.

Component name (% by weight) Products utilizing composition 1 Products utilizing Composition 2 Products utilizing composition 3 Products utilizing Composition 4 Products utilizing composition 5 Compare Products Composition 0.5000 0.1000 0.0500 0.0500 0.0500 0 Vit C 0.0050 0.0050 0.0050 0.0050 0.0050 0.0050 ethanol 0.1685 0.1685 0.1685 0.1685 0.1685 0.1685 Citrus peel oil 0.0345 0.0345 0.0345 0.0345 0.0345 0.0345 Tangerine extract 0.0070 0.0070 0.0070 0.0070 0.0070 0.0070 water 99.2850 99.6850 99.7350 99.7350 99.7350 99.7850 Sum 100.0000 100.0000 100.0000 100.0000 100.0000 100,000

Example 5. Evaluation of antimicrobial activity of a product using the composition

The antimicrobial effect on the causative agent of vaginitis of the product of Example 4 was evaluated as follows.

The antimicrobial effects of the products of Example 3 were evaluated using three species of Candida albicans (ATCC 10231), Candida glabrata (ATCC 2001) and Candida tropicalis (ATCC 42678), which are major causative bacteria of Candida albicans . The Candida bacteria used in the experiment were purchased from the Korean Microorganism Conservation Center and cultured for 3 or more times. When normal culture of the strain was confirmed, 0.1 mL of the strain was added to 10 mL of the product using the composition, followed by shaking culture at 25 DEG C for 24 hours. The control was prepared by adding 0.1 mL of the strain to 10 mL of distilled water. After the culture of the strain was completed, it was plated on an agar medium and cultured at 25 ° C for 48 hours or more. Table 5 shows the activity of reducing the vaginitis bacterium in the five products of Example 4 containing the composition as compared to the comparative product not including the composition.

Strain Compare Products Products with Composition 1 added Products to which Composition 2 is added Products with Composition 3 added Products with Composition 4 added Products to which Composition 5 is added Candida albicans 1.3 x 10 ⁵ 35% reduction 56% reduction 87% reduction 81% reduction 77% reduction Candida glabrata 1.0 x 10 ⁵ 11% reduction 15% reduction 40% reduction 33% reduction 42% reduction Candida tropicalis 7.0 x 10 ⁴ 18% reduction 21% reduction 47% reduction 35% reduction 39% reduction

* Unit: CFU / mL

Example 6. Production of female cleaner products

Production examples of the product of Example 4 are shown in Figs. 1 and 2. Fig. The female cleanser spraying device of FIG. 1 is made in a portable size with a capacity of 30 mL, and is made in a shape similar to a skin mist and designed to be portable and easy to use, and is suitable for use once or twice a day. The female cleaner disposable injection container type of FIG. 2 was manufactured to easily carry with a capacity of 50 mL. It was made to be used once a week in a vaginal container using a disposable infusion container and to prevent secondary infection by disposing the container after use. Both types of products are designed not to be reminiscent of a female cleaner, which prevents inconvenience of carrying and makes it convenient to carry with a capacity of 50mL or less, so that the user can use it anytime and anywhere conveniently.

Example 7. Production of sanitary napkin products

In order to evaluate the contribution of the composition of the present invention to the female reproductive health during the menstrual period using the sanitary napkin, the composition solution was applied to the commercially available sanitary napkin and tested. First, 39 externally sanitary napkins adhered to the outside of the vagina are put on the market. 100 mL of distilled water, 100 mL of the composition 2 solution in which 0.5% by weight of the composition 2 is dissolved in 5% ethanol aqueous solution and 0.1% by weight of the composition 3 in distilled water 3 solution was prepared. The sanitary napkins purchased were divided into three groups of 10, and the three solutions were evenly sprayed in an amount of 0.04 mL per 1 cm ² of the label layer of the sanitary napkin (the portion directly contacting the skin around the vagina). Then, it was dried in a vacuum oven (50 Torr, 40C) for 8 hours. In order to measure the amount of the composition applied to the label layer which is in direct contact with the skin around the vagina, one napkin was randomly selected from each group to separate the label layers of each napkin, and then the area of 30 cm ² was cut out, After cutting, it was placed in 250 mL of 95% ethanol and refluxed for 2 hours. The filtered solution was dried using a rotary evaporator and weighed. The results are shown in Table 6.

When each composition solution was sprayed onto the label layer, the actual applied ratio was 73 and 70%, respectively.

The sanitary napkin of the present invention is shown in Fig.

division Comparative Example Production Example 1 Production Example 2 The components contained in the solvent for coating (95% ethanol) 0 wt% Composition 2, 0.5 wt% Composition 3, 0.1 wt% The amount (mg / cm ² ) sprayed towards the label layer 0.0 0.20 mg 0.04 mg The amount actually recovered (mg / cm < ² >) in the label layer 0.0 0.146 mg 0.028 mg

Example 8. Evaluation of improvement of vaginitis symptoms

40 women (15 to 59 years old) with at least one symptom of vaginitis were recruited to use the product containing the composition of the present invention and the comparative product not containing the composition of the present invention as a symptom of each of the vaginitis-related symptoms for one week in a double blind procedure . All of the products were placed in a 50 mL capacity spray bottle and used twice a day in the vulva. Assessment was made by using VAS (Visual Analogue Scale) technique before and after 1 week of use of the product. (When the vestibulitis symptoms were felt most severely, , And the evaluation results are shown in Table 7. In addition, the improvement of the symptoms of the vaginitis syndrome, tingling, itching, flushing, and smell was indicated as O (improved) or X (not improved). The results are shown in Table 8.

division VAS before use (cm) After use VAS (cm) Improvement rate (%) Compare Products 21.5 20.2 6.0 Products with Composition 3 added 22.4 8.7 61.2 Products with Composition 4 added 20.4 7.5 63.2 Products to which Composition 5 is added 21.9 8.1 63.0

division Secretion improvement Improved tingling Itching improvement Flare improvement Improving odor Compare Products 0 ^* One 0 One 0 Products with Composition 3 added 5 6 6 5 6 Products with Composition 4 added 7 8 9 6 7 Products to which Composition 5 is added 6 8 7 7 8

* Number of people rated as O (improved)

Example 9. Evaluation of improvement of dermal toxicity symptoms

Although there is no vaginitis symptoms, 40 women (15 to 49 years old) who are experiencing side effects such as dryness, itching, and inflammation through skin irritation due to the use of female cleanser and sanitary napkin, The products containing the compositions of the present invention and the comparative products not containing them were used in a double blind procedure. All of the products were placed in a 50 mL capacity spray bottle so that the areas with peripheral side effects were sufficiently wetted. The evaluation was made using the VAS (Visual Analogue Scale) technique to assess the degree of adverse symptoms before and after 2 weeks of use. (The degree of relative feeling when compared with the 30 cm ruler when the most severe symptom was felt was expressed in cm. ) ≪ tb >

division VAS before use (cm) After use VAS (cm) Improvement rate (%) Compare Products 23.4 21.0 10.3 Products with Composition 3 added 23.1 10.7 53.7 Products with Composition 4 added 22.5 9.9 56.0 Products to which Composition 5 is added 23.4 10.3 56.0

Example 10 Evaluation of physiological symptom and sanitary wearability improvement of sanitary napkin using composition

In order to evaluate the physiological symptom and the improvement effect on the sanitary napkin wearability of the sanitary napkin product using the composition of the present invention, 30 sanitary napkins were randomly provided with the sanitary napkin of Comparative Example and Preparation Examples 1 and 2 shown in Example 7 After wearing it during the menstrual period, the physiological symptoms and the improvement of the wearability of the sanitary napkin were evaluated in comparison with the menstrual period when the ordinary sanitary napkin was used. The evaluation of physiological symptom was divided into 3 items: menses, psychological stability, and discomfort due to physiological impairment. The sanitary wearability was divided into three categories: skin irritation relief, unpleasant odor improvement, and wearing comfort improvement. O or X, respectively. Table 10 summarizes the number of people rated O (improved) per group.

division Relieve menstrual cramps Psychological stability Improved discomfort caused by menstrual impurities Skin irritation relief Improving unpleasant odor Wear comfort improvement Comparative Example 2 ^* 2 0 0 2 One Production Example 1 6 7 3 5 7 6 Production Example 2 7 8 5 8 9 9

* Number of people rated as O (improved)

As shown in the table, when Manufacturing Examples 1 and 2 using the composition of the present invention were used in comparison with Comparative Examples, it showed remarkable improvement effects in physiological symptoms, skin irritation at the time of wearing a sanitary napkin, unpleasant smell and comfort. Therefore, it can be seen that the composition of the present invention and the product thereof contribute to the promotion of female reproductive health even when applied to sanitary napkins during menstruation.

Claims (18)

Composition for maintaining or improving female reproductive health comprising phlorotannin as an active ingredient The composition according to claim 1, wherein the fluorotannine compound is at least one selected from the group consisting of fluorotannines represented by the following general formulas (1) to (12)
[Chemical Formula 1]

(2)

(3)

[Chemical Formula 4]

[Chemical Formula 5]

[Chemical Formula 6]

(7)

[Chemical Formula 8]

[Chemical Formula 9]

[Chemical formula 10]

(11)

[Chemical Formula 12]

The composition according to claim 1, wherein the composition comprises 20-100 wt% of the total fluorotannin compound The composition for maintaining or improving female reproductive organs according to claim 1, wherein the composition comprises at least one kind of phlorotannin selected from Chemical Formulas (2), (4), (5) The composition of claim 4, wherein the composition comprises 1-60 wt% of a fluorotannine of Formula 2, 0.3-20 wt% of a fluorotannine of Formula 4, 0.1-10 wt% of a fluorotannin of Formula 5, 0.1 to 5% by weight based on the total weight of the composition. The composition according to claim 4, wherein the composition comprises 1-65% by weight of phlorotannin of formula (2) and 0.3-45% by weight of phlorotannin of formula (4) The composition for maintaining or improving female reproductive health according to claim 4, wherein the composition comprises 1-45% by weight of phlorotannin of formula (5) and 0.3-45% by weight of phlorotannin of formula (8) [4] The composition of claim 4, wherein the composition comprises 0.1 to 3% by weight of a fluorotannine of Formula 1, 5 to 63% by weight of a fluorotannine of Formula 2, 1 to 3% by weight of a fluorotannin of Formula 3, 0.5 to 8% by weight of fluorotannin of formula (6), 0.1 to 1% by weight of fluorotannine of formula (7), 0.1 to 1% by weight of fluorotannine of formula (8) 0.1 to 3% by weight of phlorotannin of formula (11), 0.1 to 4% by weight of phlorotannin of formula (12), 0.1 to 2% % ≪ / RTI > of a composition for improving or improving female reproductive health The method of claim 3, wherein the composition comprises 20 to 100% by weight of fluorotannine, 0 to 30% by weight of mannitol, 0 to 25% by weight of alginic acid, 0 to 25% by weight of fucoidan, 0 to 10% by weight of fucosterol, 0 to 10% , And 0 to 10% by weight of laminaran. [4] The method of claim 3, wherein 20 to 97 wt% of fluorotannine, 1 to 30 wt% of mannitol, 1 to 25 wt% of alginic acid, 0.5 to 25 wt% of fucoidan, 0.1 to 10 wt% of fucosterol, 0.1 to 10 wt% , And 0.1 to 10% by weight of laminaran. The method of claim 1, wherein the fluorotannine compound is selected from the group consisting of Eisenia bicyclis , Eisenia arborea , Eisenia desmarestioides , Eisenia galapagensis , ( Ecklonia radiata ), Eclonia bacillus ( Ecklonia spp. ), Ecklonia cava , Ecklonia stolonifera , Sea bamboo ( Ecklonia maxima ), Ecklonia radiata , Ecklonia bicyclis ), Ecklonia biruncinate , Ecklonia buccinalis , Ecklonia caepaestipes , Ecklonia exasperta , Ecologia pasty , Ecklonia fastigiata , Ecklonia brevipes , Ecklonia arborea , Ecklonia latifolia, to extract from the folia), Eccles Catalonia Mura tea (Ecklonia muratii), Eccles Catalonia radio Kosa (Ecklonia radicosa), Eccles Catalonia retarder Diana (Ecklonia richardiana) and Eccles Catalonia La ET (at least one selected from the group consisting of Ecklonia wrightii) Composition for maintaining or improving female genital health The composition for the maintenance or improvement of female reproductive organs of the present invention as claimed in claim 1, which alleviates one or two or more vaginitis symptoms among cold airborne symptoms, vaginal discharge, tingling, itching, flushing and unpleasant smell The composition according to claim 1, further comprising a composition for maintaining or improving female reproductive organs in which at least one of physiological symptoms, psychological stability during menstruation, A female genital health maintenance or improvement product comprising the composition of claim 1 15. A female genital health maintenance or improvement product according to claim 14, characterized in that the product is applied as a liquid phase through a spray or disposable infusion bar or applied to a sanitary napkin 15. The female genital health maintenance or improvement product according to claim 14, wherein the product is a liquid product and the content of fluorotannine is 0.01 to 5% by weight based on the total weight of the liquid product. The method according to claim 14, wherein the product is a sanitary napkin products and maintaining women characterized in that the tannin is applied with 0.001 ~ 1mg / cm ² to the sanitary napkin to the flow or to improve reproductive health [Claim 15] The female genital health maintenance or improvement product according to claim 14, wherein the composition is used in an amount of 0.1 to 50 mg per day

Images